← Back to patent-cliff list
Eteplirsen
Tier C — Watch / tradeEteplirsen
Sarepta Therapeutics Inc
Originator
2016
First approval
-
Expiry (public)
$0.51B ▲
Peak sales
Nucleic acid drug
Type
Targets：Dystrophin pre-mRNA, DAG1
Brand：Exondys 51
Indications (approved)：Duchenne muscular dystrophy
Regional status
US
Approved
2016-09-19
EU
Phase III
2020-07-13
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Eteplirsen?
Approved indications include: Duchenne muscular dystrophy.
When does the Eteplirsen patent expire?
No public expiry year is available for Eteplirsen yet; this page updates once verified.
How do I get a quote for Eteplirsen intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29